MDS Virtual Congress 2020 » Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)

Meeting: MDS Virtual Congress 2020

An Open-Label, Phase 1b Study of the Neuroactive Steroid GABAA Receptor Positive Allosteric Modulator SAGE-324 in Essential Tremor

H. Colquhoun, D. Nguyen, M. Qin, A. Wehr, J. Doherty, S. Kanes (Cambridge, MA, USA)

Balance rehabilitation with a virtual reality protocol for patients with hereditary spastic paraplegia: Protocol for a clinical trial

B. Zeigelboim, G. Santos, M.I Severiano, H. Teive, B. Cavalcante-Leao (Curitiba, Brazil)

Compared the effects of probiotics and Anti-PD particles on the behavior of Parkinson’s disease mice model

X.H Zhao, Y.B Wang, J. Yang, L.Y Zhang, H.Q Liu, H.J Sui (Shanghai, China)

Comparison of Safety and Tolerability of Deutetrabenazine (DTBZ) During Titration and Maintenance in Patients With Tardive Dyskinesia (TD)

K. Anderson, H. Fernandez, H. Barkay, A. Wilhelm, N. Chaijale, A. Send, J.M Savola, M. Gordon (Washington, DC, USA)

Deutetrabenazine Reduces Involuntary Movements in Patients Most Severely Impacted by Tardive Dyskinesia in a 3-year Open-Label Extension Trial

J. Bona, H. Barkay, A. Wilhelm, N. Chaijale, M. Gordon (Atlanta, GA, USA)

Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects

Y. Masakado, A. Dekundy, A. Hanschmann, R. Kaji (Kanagawa, Japan)

High-frequency rTMS over the primary motor cortex relieves musculoskeletal pain in Parkinson’s disease: A randomized controlled trial

J. Li, T. Mi, W. Mao, J. Ma, P. Chan (Beijing, China)

Inosine 5′-Monophosphate to Raise the Serum Uric Acid Level in Patients with Multiple System Atrophy (IMPROVE-MSA study): A Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Assigned Clinical Trial

J.J Lee, J.H Yoon, S.J Kim, H.S Yoo, S.J Chung, Y.H Lee, S.Y Kang, H.W Shin, S.K Song, J.Y Hong, M.K Sunwoo, J.E Lee, J.S Baik, Y.H Sohn, P.H Lee (Goyang-si, Republic of Korea)

Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia

M. Sajatovic, A. Wilhelm, S. Finkbeiner, H. Barkay, N. Chaijale, N. Gross, M. Gordon (Cleveland, OH, USA)

Long-term safety and efficacy of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects: results of a Phase III study

F. Pagan, A. Dekundy, M. Althaus, D. Mitsikostas (Washington, DC, USA)

Long-Term Treatment With Deutetrabenazine (DTBZ) Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From the Completed, 3-year Open-Label Extension (OLE) Study

R. Hauser, H. Barkay, H. Fernandez, S. Factor, J. Jimenez-Shahed, N. Gross, L. Marinelli, A. Wilhelm, M. Gordon, J.M Savola, K. Anderson (Tampa, FL, USA)

Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia

R. Ayyagari, A. Wilhelm, J. Alexander, N. Chaijale, V. Garcia-Horton, F. Devine, B. Carroll (Boston, MA, USA)

The Impact of Antipsychotic Dose Reduction Within a Medicare Population

R. Ayyagari, F. Mu, A. Lax, B. Carroll (Boston, MA, USA)

« View all categories from the MDS Virtual Congress 2020.